Company profile: Noscendo
1.1 - Company Overview
Company description
- Provider of digital diagnostics for identification and assessment of bloodstream-associated pathogens and other infections. Offers DISQVER, a next-generation sequencing and bioinformatics platform that identifies over 16,000 microbes, including 1,500 pathogens, from a single blood sample within 24 hours.
Products and services
- Bloodstream Pathogen Identification and Assessment: Diagnostics-focused service that identifies and assesses bloodstream-associated pathogens, addressing infections occurring in the bloodstream per Noscendo’s stated dedication
- DISQVER: NGS-based digital diagnostics platform using bioinformatics to identify over 16,000 microbes, including 1,500 pathogens, from a single blood sample within 24 hours
- Other Infection Identification and Assessment: Infection-focused service that identifies and assesses other infections beyond bloodstream-associated cases, reflecting Noscendo’s dedication to diagnostic evaluation of infectious agents.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Noscendo
NRx Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics targeting central nervous system disorders and pulmonary diseases, with investigational products including NRX-101 for suicidal bipolar depression (Phase 3), chronic pain (Phase 2), and PTSD (Phase 2), and NRX-100 (IV ketamine) for severe bipolar depression post stabilization from a suicidal crisis (Phase 3).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NRx Pharmaceuticals company profile →
Revelation Biosciences
HQ: United States
Website
- Description: Provider of immunologic therapeutics and diagnostics, including Gemini, a proprietary PHAD formulation for systemic administration for prevention of post-surgical infection, acute kidney injury, and chronic kidney disease; GEM-AKI and GEM-CKD therapies that redirect the innate immune response; and GEM-SSI for prevention or treatment of healthcare-associated bacterial infections (post-surgical/post-burn, UTIs, sepsis, antibiotic-resistant).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Revelation Biosciences company profile →
Enantigen
HQ: United States
Website
- Description: Provider of discovery, development, and commercialization of novel drugs for life-threatening infectious diseases, with a primary focus on oral therapeutics for the treatment of hepatitis; located at the Pennsylvania Biotechnology Center.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enantigen company profile →
NanoCures
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology and infectious disease immunity platforms, including: Cures Platform targeting specific genomic and molecular pathways to yield multiple therapeutics; Data/AI Platform using biometric, genomic, molecular, and environmental data with AI/ML to detect diseases early and guide new cure development; and Developer Platform offering resources, data, and tools to lower barriers and encourage innovation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoCures company profile →
Cerus
HQ: United States
Website
- Description: Provider of blood safety pathogen reduction systems: INTERCEPT Blood System for Platelets and Plasma (available globally with regulatory approvals); INTERCEPT Red Blood Cell System (under regulatory review in Europe and in late-stage clinical development in the US); INTERCEPT Blood System of Cryoprecipitation to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex to treat and control bleeding associated with fibrinogen deficiency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerus company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Noscendo
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Noscendo
2.2 - Growth funds investing in similar companies to Noscendo
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Noscendo
4.2 - Public trading comparable groups for Noscendo
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →